Published in Urology on March 01, 2012
Perspectives on treatment of metastatic castration-resistant prostate cancer. Oncologist (2013) 1.42
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer. Asian J Androl (2013) 1.11
Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice. Prostate Int (2013) 0.79
Is there still a place for docetaxel rechallenge in prostate cancer? World J Clin Oncol (2015) 0.79
Bioclinical parameters driving decision-making of subsequent lines of treatment in metastatic castration-resistant prostate cancer. Biomed Res Int (2014) 0.78
2-weekly docetaxel: issues for clinical practice. Cancer Biol Ther (2015) 0.75
Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer: A Case Report and Review of Literature. Medicine (Baltimore) (2016) 0.75
Novel non-AR therapeutic targets in castrate resistant prostate cancer. Transl Androl Urol (2013) 0.75
Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res (2007) 3.12
The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol (2006) 2.77
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res (2011) 2.27
Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial. J Clin Oncol (2002) 1.98
High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer (2003) 1.49
M-CAM expression as marker of poor prognosis in epithelial ovarian cancer. Int J Cancer (2006) 1.38
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial. J Clin Oncol (2011) 1.36
Evidence of the effect of adjunct ultrasound screening in women with mammography-negative dense breasts: interval breast cancers at 1 year follow-up. Eur J Cancer (2011) 1.33
Activity of Pemetrexed on brain metastases from Non-Small Cell Lung Cancer. Lung Cancer (2009) 1.30
Pain and quality of life after surgery for breast cancer. Breast Cancer Res Treat (2003) 1.29
Breast screening with ultrasound in women with mammography-negative dense breasts: evidence on incremental cancer detection and false positives, and associated cost. Eur J Cancer (2008) 1.28
Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer (2002) 1.12
Use of penile extender device in the treatment of penile curvature as a result of Peyronie's disease. Results of a phase II prospective study. J Sex Med (2008) 1.08
Experience in designing and evaluating a Teleconsultation System supporting shared care of oncological patients. AMIA Annu Symp Proc (2003) 1.07
Second-line chemotherapy with irinotecan plus carmustine in glioblastoma recurrent or progressive after first-line temozolomide chemotherapy: a phase II study of the Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). J Clin Oncol (2004) 1.05
Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04
Impact of third-generation drugs on the activity of first-line chemotherapy in advanced non-small cell lung cancer: a meta-analytical approach. Oncologist (2009) 1.02
Pathological, biological and clinical characteristics, and surgical management, of elderly women with breast cancer. Crit Rev Oncol Hematol (2006) 0.94
We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC. Future Oncol (2014) 0.93
The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. Free Radic Res (2003) 0.92
Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. J Environ Pathol Toxicol Oncol (2003) 0.92
Simultaneous determination of gemcitabine and its main metabolite, dFdU, in plasma of patients with advanced non-small-cell lung cancer by high-performance liquid chromatography-tandem mass spectrometry. J Mass Spectrom (2008) 0.92
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. Clin Genitourin Cancer (2013) 0.90
An ontology of cancer therapies supporting interoperability and data consistency in EPRs. Comput Biol Med (2013) 0.90
Systemic therapies for recurrent and/or metastatic salivary gland cancers. Expert Rev Anticancer Ther (2008) 0.89
A pilot phase-II prospective study to test the 'efficacy' and tolerability of a penile-extender device in the treatment of 'short penis'. BJU Int (2008) 0.89
Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther (2012) 0.88
Pathological changes of high-grade prostatic intraepithelial neoplasia and prostate cancer after monotherapy with bicalutamide 150 mg. BJU Int (2006) 0.87
Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: preliminary results of the MITO-2 randomized trial. BMC Cancer (2006) 0.87
Orbital metastasis as the first sign of "Dormant" breast cancer dissemination 25 years after mastectomy. Jpn J Ophthalmol (2008) 0.86
The usefulness of antibiotic prophylaxis in invasive urodynamics in postmenopausal female subjects. Int Urogynecol J Pelvic Floor Dysfunct (2008) 0.85
Phase I study of gemcitabine and radiotherapy plus cisplatin after transurethral resection as conservative treatment for infiltrating bladder cancer. Int J Radiat Oncol Biol Phys (2003) 0.85
Diagnostic value of automated Her2 evaluation in breast cancer: a study on 272 equivocal (score 2+) Her2 immunoreactive cases using an FDA approved system. Appl Immunohistochem Mol Morphol (2011) 0.85
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting. Future Oncol (2014) 0.85
Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol (2011) 0.85
Trimodality treatment in the conservative management of infiltrating bladder cancer: a critical review of the literature. Crit Rev Oncol Hematol (2012) 0.84
Prospective evaluation of quality of life after interstitial brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys (2006) 0.84
Brain metastases from prostate cancer: an emerging clinical problem with implications for the future therapeutic scenario. Future Oncol (2012) 0.83
PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy. Virchows Arch (2012) 0.83
CDC25A protein stability represents a previously unrecognized target of HER2 signaling in human breast cancer: implication for a potential clinical relevance in trastuzumab treatment. Neoplasia (2013) 0.83
Evaluation of toxicity and quality of life using a diary card during postoperative radiotherapy for rectal cancer. Dis Colon Rectum (2002) 0.83
Late events and clinical prognostic factors in stage I non small cell lung cancer. Lung Cancer (2002) 0.83
Prognostic value of thymidine phosphorylase expression in breast carcinoma. Int J Cancer (2002) 0.82
Frequency of brain metastases from prostate cancer: an 18-year single-institution experience. J Neurooncol (2012) 0.82
Docetaxel, with or without estramustine phosphate, as first-line chemotherapy for hormone-refractory prostate cancer: results of a multicentre, randomized phase II trial. BJU Int (2008) 0.82
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitor. Future Oncol (2013) 0.82
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme. BJU Int (2014) 0.82
Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide. Future Oncol (2014) 0.81
Basal level and behaviour of cytokines in a randomized outpatient trial comparing chemotherapy and biochemotherapy in metastatic melanoma. Melanoma Res (2006) 0.81
LZTS1 downregulation confers paclitaxel resistance and is associated with worse prognosis in breast cancer. Oncotarget (2014) 0.80
Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. Urol Oncol (2008) 0.80
Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat (2011) 0.80
A phase II study of liposomal doxorubicin in recurrent epithelial ovarian carcinoma. Tumori (2005) 0.79
Prognostic significance of laminin, laminin receptor, and bone marrow micrometastases in breast cancer patients: are these markers of aggressive behavior and metastatic potential? Appl Immunohistochem Mol Morphol (2003) 0.79
Pemetrexed as second-line chemotherapy for castration-resistant prostate cancer after docetaxel failure: results from a phase II study. Urol Oncol (2011) 0.79
Multicenter phase 2 study of combined gemcitabine and epirubicin as second-line treatment for patients with advanced ovarian cancer. Int J Gynecol Cancer (2010) 0.79
PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch (2014) 0.79
Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther (2012) 0.79
c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. Endocr Relat Cancer (2009) 0.79
Pharmacokinetic study of gemcitabine, given as prolonged infusion at fixed dose rate, in combination with cisplatin in patients with advanced non-small-cell lung cancer. Cancer Chemother Pharmacol (2010) 0.79
Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: a phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity. Int J Oncol (2002) 0.79
Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial. Breast (2013) 0.78
Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial. BJU Int (2011) 0.78
Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab. Pharmacogenomics (2014) 0.78
Biochemical and objective response to abiraterone acetate withdrawal: incidence and clinical relevance of a new scenario for castration-resistant prostate cancer. Urology (2013) 0.78
Six-week induction chemotherapy followed by concomitant chemoradiation therapy in stage IV head and neck cancer: a phase II study with organ-sparing purposes. Oncol Rep (2003) 0.77
An evaluation of the pharmacokinetics and clinical use of vinorelbine for NSCLC treatment. Expert Opin Drug Metab Toxicol (2013) 0.77
Optimal Sequencing of New Drugs in Metastatic Castration-Resistant Prostate Cancer: Dream or Reality? Curr Drug Targets (2016) 0.77